Clinical Trial Update: CERebrolysin In CADASIL [Phase 2]

View source ↗

Summary

Phase 2 trial update for CERebrolysin in CADASIL; the study is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy

Drugs mentioned

• Cerebrolysin

Snippet

Sponsor: Ever Neuro Pharma GmbH | Conditions: Cadasil | Phase 2 | Status: ACTIVE_NOT_RECRUITING